Organization (Industry)
Integra LifeSciences Corporation
ClinicalTrials.gov lists Integra LifeSciences Corporation as lead sponsor of 93 trials, counting the companies grouped under it. Integra LifeSciences Corporation itself has 1 active development program and 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Integra LifeSciences Corporation and 3 companies grouped under it: 93 lead-sponsored trials (82 its own, 11 in the grouped companies) and 8 legal-entity registrations (8 its own, 0 in the grouped companies).
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Companies grouped under this page (3)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| Integra LifeSciences Services | 9 | 0 |
| Ascension Orthopedics, Inc. | 1 | 0 |
| Surgical Innovation Associates, Inc. | 1 | 0 |
Disease areas (64)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 17 |
| Diabetic Foot | 16 |
| Diabetic Neuropathies | 16 |
| Otitis Media | 9 |
| Sinusitis | 6 |
Showing 5 of 64 disease areas.
Trials by start year as sponsor or collaborator (23)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 4 |
| 2023 | 7 |
| 2022 | 5 |
| 2021 | 3 |
| 2020 | 6 |
| 2019 | 5 |
| 2018 | 4 |
| 2017 | 6 |
Showing 10 of 23 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (1)
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Medical Management | Sinusitis | Not reported | 1 |
Approved assets (1)
| Drug | Trials |
|---|---|
| Collagenase | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 36% hit target (n=25) | 57% on time (n=23) |
Journals published in (82)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Plastic and reconstructive surgery | 8 |
| Journal of the American College of Surgeons | 6 |
| Gastrointestinal endoscopy | 4 |
| Neurocritical care | 4 |
| The Cochrane database of systematic reviews | 4 |
Showing 5 of 82 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 131 | 20 | 2024-12-10 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 1,635,245,000 | -516,474,000 | 98,971,000 |
| 2024 | 1,610,527,000 | -6,944,000 | 115,377,000 |
| 2023 | 1,541,573,000 | 67,741,000 | 104,192,000 |
| 2022 | 1,557,666,000 | 180,550,000 | 101,193,000 |
| 2021 | 1,542,448,000 | 169,075,000 | 93,051,000 |
| 2020 | 1,371,868,000 | 133,892,000 | 77,381,000 |
| 2019 | 1,517,557,000 | 50,201,000 | 79,573,000 |
| 2018 | 1,472,441,000 | 60,801,000 | 78,041,000 |
| 2017 | 1,188,236,000 | 64,743,000 | 63,455,000 |
| 2016 | 992,075,000 | 74,564,000 | 58,155,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (27)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-04-10 | Debt financing | not disclosed | Sec extracted |
| 2026-02-26 | Follow-on offering | not disclosed | Edgar offerings |
| 2025-06-06 | Debt financing | not disclosed | Sec extracted |
| 2024-05-16 | Other financing | not disclosed | Sec extracted |
| 2024-05-09 | Other financing | not disclosed | Sec extracted |
Showing 5 of 27 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 15 |
FDA recalls (277)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| OmniTract Surgical Retractor System, which includes 633 of the firm s product codes. | Class II | 2026-06-05 |
| Codman CerebroFlo EVD Catheter with Endexo Technology. Contains 5 sets. Product ID: 37.550.501. The CerebroFlo EVD Catheter is a 3.3 mm diameter (10 Fr.), 35 cm long polyurethane catheter for diverting cerebrospinal fluid (CSF) from the ventricles of the brain through a series of drainage holes near the catheter's bullet shaped tip. | Class II | 2026-04-10 |
| Cytal Wound Matrix 2-Layer 5x5 cm. Product ID: WSM0505. | Class II | 2026-03-19 |
| Cytal Wound Matrix 2-Layer 7x10 cm. Product ID: WSM0710. | Class II | 2026-03-19 |
| Cytal Wound Matrix 2-Layer 10x15 cm. Product ID: WSM1015. | Class II | 2026-03-19 |
Showing 5 of 277 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 3 | 2024-06-10 |
Manufacturing and distribution sites (3)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| INTEGRA LIFESCIENCES CORPORATION | PLAINSBORO, US | FDA | |
| Integra LifeSciences Corporation | Princeton, US | FDA | |
| INTEGRA LIFESCIENCES CORPORATION | CINCINNATI, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Johnson & Johnson | Co sponsors trial with | 1 |
| Allegheny Health Network | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| US Biotest (United States) | Co sponsors trial with | 1 |
| Avania | Co sponsors trial with | 1 |
Latest dated events (566)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-05 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-10 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2026-04-10 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-19 | FDA recall | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
Showing 5 of 566 events.
Biomarker capability evidence (26)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ADM | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial sponsor | Named in trial inclusion criteria |
| HGD | Trial collaborator | Named in trial inclusion criteria |
| PVR | Trial sponsor | Named in trial inclusion criteria |
| RARS1 | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 26 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: fda warning letters, fda untitled letters, clia clinical laboratory certificates, and biomarkers this organization publishes on.